Vaccine safety surveillance — Phase 1 signal detection (VAERS)

This page reports observed after vaccination (spontaneous reports) and within-VAERS reporting disproportionality. It does not establish that an event is statistically associated in a population with a denominator, clinically attributed, mechanistically supported, or causally established. VAERS report counts divided by doses are not incidence.

Calibration / falsification. COVID-19 vaccine reports also met the locked hit rule for negative-control outcomes (appendicitis, distal_radius_fracture). That pattern is expected if stimulated reporting or a larger, more visible product inflates many unrelated PTs — it is evidence of residual bias, not a family of injuries. Positive-control myocarditis/pericarditis signals must be read against this background. Anaphylaxis in the 0–1 day window did not meet PRR > 1.5 in this extract.

Protocol phase1-vaers-signal-detection v1.0.0 is locked. A hit means FDR < 0.05 and PRR > 1.5 and ≥5 reports in the prespecified primary window, comparing this vaccine’s VAERS reports with other vaccines’ VAERS reports. That is Level 1 (passive signal) at most. SCCS, cohort incidence, infection adjustment, clinical attribution, and mechanistic tests are not run at Phase 1 — those modules refuse VAERS as input.

Analysis anl_0c98a7f0ae82 · ontology 2026.09.1 · code v0.1.0 · 1,162,127 unique VAERS reports · 14 vaccine groups · 51 hits / 280 tests

What each number is

Reported following vaccinationVAERS spontaneous report mentioning the locked MedDRA set.

Disproportional in VAERSPRR vs other vaccines in the same database (this table).

Epidemiologically associatedNot computed. Needs SCCS/cohort with person-time (Phase 4).

Clinically attributedNot computed. Needs case definition + adjudication (Phase 6).

Causally establishedNot claimed. Requires replicated epi + attribution + mechanism.

COVID-19 vaccines — locked positive controls

Myocarditis (0–7 d) and anaphylaxis (0–1 d) are methodological benchmarks. If they do not appear as reporting signals, investigate the pipeline before reading novel outcomes. A VAERS PRR is still not incidence.

Vaccine	Outcome	Window	n (window)	PRR	95% CI	Hit	Grade
covid	Myocarditis	0-7	1162	10.52	8.21–13.47	yes	L1
covid	Pericarditis	0-7	946	4.79	3.95–5.80	yes	L1
covid	Anaphylaxis	0-1	1660	1.12	1.03–1.22	no	L0

Negative-control outcomes (all vaccines)

Appendicitis and distal radius fracture have no credible vaccine causal pathway. PRR substantially above 1 across many vaccines suggests residual reporting bias, not a family of injuries.

Vaccine	Outcome	Window	n (window)	PRR	95% CI	Hit	Grade
covid	Appendicitis (negative control)	0-28	479	9.54	6.59–13.79	yes	L1
covid	Distal radius fracture (negative control)	0-28	32	2.39	1.10–5.18	yes	L1
dtap	Appendicitis (negative control)	0-28	3	0.07	0.02–0.21	no	L0
dtap	Distal radius fracture (negative control)	0-28	3	0.93	0.29–3.03	no	L0
hepatitis-a	Appendicitis (negative control)	0-28	3	0.14	0.04–0.44	no	L0
hepatitis-a	Distal radius fracture (negative control)	0-28	1	0.60	0.08–4.40	no	L0
hepatitis-b	Appendicitis (negative control)	0-28	1	0.81	0.11–5.78	no	L0
hepatitis-b	Distal radius fracture (negative control)	0-28	0	0.00	—–—	no	L0
hib	Appendicitis (negative control)	0-28	0	0.00	—–—	no	L0
hib	Distal radius fracture (negative control)	0-28	0	0.00	—–—	no	L0
hpv	Appendicitis (negative control)	0-28	14	0.96	0.57–1.64	no	L0
hpv	Distal radius fracture (negative control)	0-28	2	1.79	0.43–7.42	no	L0
influenza	Appendicitis (negative control)	0-28	5	0.09	0.04–0.21	no	L0
influenza	Distal radius fracture (negative control)	0-28	2	0.47	0.11–1.95	no	L0
meningococcal	Appendicitis (negative control)	0-28	4	0.30	0.11–0.79	no	L0
meningococcal	Distal radius fracture (negative control)	0-28	1	0.96	0.13–7.00	no	L0
mmr	Appendicitis (negative control)	0-28	1	0.04	0.01–0.32	no	L0
mmr	Distal radius fracture (negative control)	0-28	0	0.00	—–—	no	L0
other	Appendicitis (negative control)	0-28	7	0.29	0.14–0.60	no	L0
other	Distal radius fracture (negative control)	0-28	2	1.08	0.26–4.47	no	L0
pcv	Appendicitis (negative control)	0-28	2	0.06	0.01–0.23	no	L0
pcv	Distal radius fracture (negative control)	0-28	2	0.75	0.18–3.10	no	L0
polio	Appendicitis (negative control)	0-28	0	0.00	—–—	no	L0
polio	Distal radius fracture (negative control)	0-28	0	0.00	—–—	no	L0
rotavirus	Appendicitis (negative control)	0-28	1	0.13	0.02–0.92	no	L0
rotavirus	Distal radius fracture (negative control)	0-28	0	0.00	—–—	no	L0
varicella	Appendicitis (negative control)	0-28	2	0.04	0.01–0.18	no	L0
varicella	Distal radius fracture (negative control)	0-28	2	0.58	0.14–2.42	no	L0

Hits under the locked rule (51)

Vaccine	Outcome	Window	n (window)	PRR	95% CI	Hit	Grade
covid	TTS / thrombosis with thrombocytopenia	4-30	84	50.17	6.98–360.33	yes	L1
covid	Thrombotic disease	0-28	4509	14.03	12.14–16.20	yes	L1
covid	Myocarditis	0-7	1162	10.52	8.21–13.47	yes	L1
covid	Appendicitis (negative control)	0-28	479	9.54	6.59–13.79	yes	L1
influenza	Guillain-Barré syndrome	1-42	911	7.45	6.83–8.14	yes	L1
hepatitis-b	Guillain-Barré syndrome	1-42	30	6.28	4.39–8.99	yes	L1
hpv	POTS	0-28	43	5.30	3.84–7.31	yes	L1
hib	Encephalitis	0-28	40	4.88	3.54–6.73	yes	L1
covid	Pericarditis	0-7	946	4.79	3.95–5.80	yes	L1
hpv	Optic neuritis	0-28	22	4.33	2.78–6.74	yes	L1
influenza	Transverse myelitis	0-28	127	4.30	3.48–5.31	yes	L1
rotavirus	Death (as reported)	0-28	332	4.07	3.64–4.54	yes	L1
hepatitis-b	Encephalitis	0-28	5	3.84	1.59–9.25	yes	L1
meningococcal	Optic neuritis	0-28	16	3.35	2.01–5.59	yes	L1
hepatitis-a	Encephalitis	0-28	63	3.10	2.38–4.03	yes	L1
other	Guillain-Barré syndrome	1-42	259	3.04	2.67–3.46	yes	L1
mmr	Encephalitis	0-28	63	3.00	2.31–3.90	yes	L1
hib	Death (as reported)	0-28	254	2.87	2.54–3.26	yes	L1
hepatitis-b	SFN-2 peripheral-neuropathy phenotype	0-28	10	2.86	1.54–5.32	yes	L1
influenza	Optic neuritis	0-28	47	2.84	2.04–3.94	yes	L1
mmr	Thrombocytopenia	0-28	204	2.81	2.43–3.24	yes	L1
covid	Bell's palsy	0-28	3315	2.80	2.58–3.04	yes	L1
polio	Encephalitis	0-28	19	2.77	1.75–4.38	yes	L1
rotavirus	Encephalitis	0-28	22	2.77	1.81–4.24	yes	L1
covid	Arrhythmia	0-28	8484	2.76	2.62–2.90	yes	L1
dtap	Encephalitis	0-28	102	2.66	2.15–3.30	yes	L1
hib	Seizure	0-7	229	2.47	2.17–2.82	yes	L1
covid	Death (as reported)	0-28	4551	2.41	2.26–2.57	yes	L1
covid	Distal radius fracture (negative control)	0-28	32	2.39	1.10–5.18	yes	L1
other	Encephalitis	0-28	54	2.26	1.71–3.00	yes	L1
meningococcal	Seizure	0-7	332	2.23	2.00–2.49	yes	L1
pcv	Encephalitis	0-28	71	2.14	1.67–2.75	yes	L1
meningococcal	Guillain-Barré syndrome	1-42	108	2.14	1.76–2.59	yes	L1
hpv	Seizure	0-7	342	2.09	1.87–2.32	yes	L1
covid	POTS	0-28	246	2.01	1.55–2.61	yes	L1
rotavirus	Seizure	0-7	176	2.01	1.73–2.33	yes	L1
influenza	Encephalitis	0-28	98	1.97	1.58–2.45	yes	L1
hib	Thrombocytopenia	0-28	57	1.93	1.49–2.52	yes	L1
meningococcal	Encephalitis	0-28	25	1.81	1.21–2.70	yes	L1
meningococcal	Transverse myelitis	0-28	18	1.81	1.13–2.90	yes	L1
dtap	Transverse myelitis	0-28	53	1.81	1.35–2.41	yes	L1
hepatitis-a	Thrombocytopenia	0-28	132	1.80	1.50–2.14	yes	L1
other	Transverse myelitis	0-28	31	1.76	1.22–2.55	yes	L1
covid	SFN-3 autonomic phenotype	0-28	19848	1.72	1.68–1.77	yes	L1
covid	SFN-2 peripheral-neuropathy phenotype	0-28	1076	1.70	1.51–1.91	yes	L1
dtap	Seizure	0-7	734	1.63	1.51–1.76	yes	L1
hepatitis-b	Seizure	0-7	23	1.61	1.07–2.42	yes	L1
polio	Anaphylaxis	0-1	52	1.59	1.21–2.10	yes	L1
other	Optic neuritis	0-28	14	1.58	0.92–2.73	yes	L1
hepatitis-a	Seizure	0-7	364	1.55	1.39–1.72	yes	L1
hpv	Encephalitis	0-28	23	1.50	0.99–2.28	yes	L1

COVID-19 — all locked outcomes

Vaccine	Outcome	Window	n (window)	PRR	95% CI	Hit	Grade
covid	Myocarditis	0-7	1162	10.52	8.21–13.47	yes	L1
covid	Pericarditis	0-7	946	4.79	3.95–5.80	yes	L1
covid	Arrhythmia	0-28	8484	2.76	2.62–2.90	yes	L1
covid	Thrombotic disease	0-28	4509	14.03	12.14–16.20	yes	L1
covid	SFN-1 symptom phenotype	0-28	75847	1.11	1.10–1.12	no	L0
covid	SFN-2 peripheral-neuropathy phenotype	0-28	1076	1.70	1.51–1.91	yes	L1
covid	SFN-3 autonomic phenotype	0-28	19848	1.72	1.68–1.77	yes	L1
covid	POTS	0-28	246	2.01	1.55–2.61	yes	L1
covid	Guillain-Barré syndrome	1-42	466	0.18	0.16–0.20	no	L0
covid	Transverse myelitis	0-28	144	0.35	0.28–0.43	no	L0
covid	Encephalitis	0-28	203	0.36	0.30–0.42	no	L0
covid	Optic neuritis	0-28	82	0.43	0.33–0.58	no	L0
covid	Bell's palsy	0-28	3315	2.80	2.58–3.04	yes	L1
covid	Seizure	0-7	3887	1.14	1.08–1.20	no	L0
covid	Thrombocytopenia	0-28	1190	1.05	0.96–1.16	no	L0
covid	TTS / thrombosis with thrombocytopenia	4-30	84	50.17	6.98–360.33	yes	L1
covid	Anaphylaxis	0-1	1660	1.12	1.03–1.22	no	L0
covid	Death (as reported)	0-28	4551	2.41	2.26–2.57	yes	L1
covid	Appendicitis (negative control)	0-28	479	9.54	6.59–13.79	yes	L1
covid	Distal radius fracture (negative control)	0-28	32	2.39	1.10–5.18	yes	L1

Full catalogue (every vaccine × outcome)

Primary window is outcome-specific and was locked before this run. Secondary window histograms live in vaccine_safety/data/derived/phase1_signals.json. Do not promote a secondary window to primary after seeing these numbers.

Vaccine	Outcome	Window	n (window)	PRR	95% CI	Hit	Grade
covid	Myocarditis	0-7	1162	10.52	8.21–13.47	yes	L1
covid	Pericarditis	0-7	946	4.79	3.95–5.80	yes	L1
covid	Arrhythmia	0-28	8484	2.76	2.62–2.90	yes	L1
covid	Thrombotic disease	0-28	4509	14.03	12.14–16.20	yes	L1
covid	SFN-1 symptom phenotype	0-28	75847	1.11	1.10–1.12	no	L0
covid	SFN-2 peripheral-neuropathy phenotype	0-28	1076	1.70	1.51–1.91	yes	L1
covid	SFN-3 autonomic phenotype	0-28	19848	1.72	1.68–1.77	yes	L1
covid	POTS	0-28	246	2.01	1.55–2.61	yes	L1
covid	Guillain-Barré syndrome	1-42	466	0.18	0.16–0.20	no	L0
covid	Transverse myelitis	0-28	144	0.35	0.28–0.43	no	L0
covid	Encephalitis	0-28	203	0.36	0.30–0.42	no	L0
covid	Optic neuritis	0-28	82	0.43	0.33–0.58	no	L0
covid	Bell's palsy	0-28	3315	2.80	2.58–3.04	yes	L1
covid	Seizure	0-7	3887	1.14	1.08–1.20	no	L0
covid	Thrombocytopenia	0-28	1190	1.05	0.96–1.16	no	L0
covid	TTS / thrombosis with thrombocytopenia	4-30	84	50.17	6.98–360.33	yes	L1
covid	Anaphylaxis	0-1	1660	1.12	1.03–1.22	no	L0
covid	Death (as reported)	0-28	4551	2.41	2.26–2.57	yes	L1
covid	Appendicitis (negative control)	0-28	479	9.54	6.59–13.79	yes	L1
covid	Distal radius fracture (negative control)	0-28	32	2.39	1.10–5.18	yes	L1
dtap	Myocarditis	0-7	16	0.15	0.09–0.25	no	L0
dtap	Pericarditis	0-7	16	0.18	0.11–0.29	no	L0
dtap	Arrhythmia	0-28	373	0.43	0.39–0.48	no	L0
dtap	Thrombotic disease	0-28	24	0.06	0.04–0.09	no	L0
dtap	SFN-1 symptom phenotype	0-28	5875	0.61	0.60–0.63	no	L0
dtap	SFN-2 peripheral-neuropathy phenotype	0-28	43	0.35	0.26–0.47	no	L0
dtap	SFN-3 autonomic phenotype	0-28	1241	0.56	0.53–0.59	no	L0
dtap	POTS	0-28	7	0.26	0.12–0.55	no	L0
dtap	Guillain-Barré syndrome	1-42	226	1.46	1.28–1.68	no	L0
dtap	Transverse myelitis	0-28	53	1.81	1.35–2.41	yes	L1
dtap	Encephalitis	0-28	102	2.66	2.15–3.30	yes	L1
dtap	Optic neuritis	0-28	18	1.17	0.72–1.90	no	L0
dtap	Bell's palsy	0-28	87	0.25	0.21–0.31	no	L0
dtap	Seizure	0-7	734	1.63	1.51–1.76	yes	L1
dtap	Thrombocytopenia	0-28	141	0.94	0.79–1.12	no	L0
dtap	TTS / thrombosis with thrombocytopenia	4-30	0	0.00	—–—	no	L0
dtap	Anaphylaxis	0-1	209	1.03	0.90–1.19	no	L0
dtap	Death (as reported)	0-28	503	1.12	1.02–1.23	no	L0
dtap	Appendicitis (negative control)	0-28	3	0.07	0.02–0.21	no	L0
dtap	Distal radius fracture (negative control)	0-28	3	0.93	0.29–3.03	no	L0
hepatitis-a	Myocarditis	0-7	10	0.19	0.10–0.36	no	L0
hepatitis-a	Pericarditis	0-7	8	0.18	0.09–0.36	no	L0
hepatitis-a	Arrhythmia	0-28	158	0.37	0.31–0.43	no	L0
hepatitis-a	Thrombotic disease	0-28	11	0.06	0.03–0.10	no	L0
hepatitis-a	SFN-1 symptom phenotype	0-28	2052	0.42	0.41–0.44	no	L0
hepatitis-a	SFN-2 peripheral-neuropathy phenotype	0-28	19	0.31	0.20–0.49	no	L0
hepatitis-a	SFN-3 autonomic phenotype	0-28	742	0.67	0.63–0.72	no	L0
hepatitis-a	POTS	0-28	6	0.45	0.20–1.01	no	L0
hepatitis-a	Guillain-Barré syndrome	1-42	81	0.99	0.80–1.24	no	L0
hepatitis-a	Transverse myelitis	0-28	17	1.07	0.66–1.74	no	L0
hepatitis-a	Encephalitis	0-28	63	3.10	2.38–4.03	yes	L1
hepatitis-a	Optic neuritis	0-28	11	1.41	0.77–2.59	no	L0
hepatitis-a	Bell's palsy	0-28	57	0.34	0.26–0.44	no	L0
hepatitis-a	Seizure	0-7	364	1.55	1.39–1.72	yes	L1
hepatitis-a	Thrombocytopenia	0-28	132	1.80	1.50–2.14	yes	L1
hepatitis-a	TTS / thrombosis with thrombocytopenia	4-30	0	0.00	—–—	no	L0
hepatitis-a	Anaphylaxis	0-1	98	0.95	0.77–1.16	no	L0
hepatitis-a	Death (as reported)	0-28	187	0.80	0.69–0.93	no	L0
hepatitis-a	Appendicitis (negative control)	0-28	3	0.14	0.04–0.44	no	L0
hepatitis-a	Distal radius fracture (negative control)	0-28	1	0.60	0.08–4.40	no	L0
hepatitis-b	Myocarditis	0-7	2	0.67	0.17–2.70	no	L0
hepatitis-b	Pericarditis	0-7	1	0.39	0.05–2.76	no	L0
hepatitis-b	Arrhythmia	0-28	14	0.56	0.33–0.95	no	L0
hepatitis-b	Thrombotic disease	0-28	0	0.00	—–—	no	L0
hepatitis-b	SFN-1 symptom phenotype	0-28	321	1.14	1.03–1.26	no	L0
hepatitis-b	SFN-2 peripheral-neuropathy phenotype	0-28	10	2.86	1.54–5.32	yes	L1
hepatitis-b	SFN-3 autonomic phenotype	0-28	94	1.46	1.20–1.78	no	L0
hepatitis-b	POTS	0-28	1	1.30	0.18–9.25	no	L0
hepatitis-b	Guillain-Barré syndrome	1-42	30	6.28	4.39–8.99	yes	L1
hepatitis-b	Transverse myelitis	0-28	1	1.06	0.15–7.54	no	L0
hepatitis-b	Encephalitis	0-28	5	3.84	1.59–9.25	yes	L1
hepatitis-b	Optic neuritis	0-28	1	2.13	0.30–15.19	no	L0
hepatitis-b	Bell's palsy	0-28	9	0.93	0.48–1.78	no	L0
hepatitis-b	Seizure	0-7	23	1.61	1.07–2.42	yes	L1
hepatitis-b	Thrombocytopenia	0-28	5	1.11	0.46–2.67	no	L0
hepatitis-b	TTS / thrombosis with thrombocytopenia	4-30	0	0.00	—–—	no	L0
hepatitis-b	Anaphylaxis	0-1	6	0.98	0.44–2.17	no	L0
hepatitis-b	Death (as reported)	0-28	2	0.15	0.04–0.58	no	L0
hepatitis-b	Appendicitis (negative control)	0-28	1	0.81	0.11–5.78	no	L0
hepatitis-b	Distal radius fracture (negative control)	0-28	0	0.00	—–—	no	L0
hib	Myocarditis	0-7	1	0.05	0.01–0.36	no	L0
hib	Pericarditis	0-7	3	0.17	0.06–0.54	no	L0
hib	Arrhythmia	0-28	100	0.60	0.49–0.73	no	L0
hib	Thrombotic disease	0-28	1	0.01	0.00–0.09	no	L0
hib	SFN-1 symptom phenotype	0-28	92	0.05	0.04–0.06	no	L0
hib	SFN-2 peripheral-neuropathy phenotype	0-28	0	0.00	—–—	no	L0
hib	SFN-3 autonomic phenotype	0-28	41	0.09	0.07–0.13	no	L0
hib	POTS	0-28	0	0.00	—–—	no	L0
hib	Guillain-Barré syndrome	1-42	9	0.28	0.14–0.53	no	L0
hib	Transverse myelitis	0-28	6	0.96	0.43–2.14	no	L0
hib	Encephalitis	0-28	40	4.88	3.54–6.73	yes	L1
hib	Optic neuritis	0-28	0	0.00	—–—	no	L0
hib	Bell's palsy	0-28	9	0.14	0.07–0.26	no	L0
hib	Seizure	0-7	229	2.47	2.17–2.82	yes	L1
hib	Thrombocytopenia	0-28	57	1.93	1.49–2.52	yes	L1
hib	TTS / thrombosis with thrombocytopenia	4-30	0	0.00	—–—	no	L0
hib	Anaphylaxis	0-1	22	0.54	0.35–0.81	no	L0
hib	Death (as reported)	0-28	254	2.87	2.54–3.26	yes	L1
hib	Appendicitis (negative control)	0-28	0	0.00	—–—	no	L0
hib	Distal radius fracture (negative control)	0-28	0	0.00	—–—	no	L0
hpv	Myocarditis	0-7	10	0.28	0.15–0.52	no	L0
hpv	Pericarditis	0-7	8	0.26	0.13–0.52	no	L0
hpv	Arrhythmia	0-28	176	0.59	0.51–0.68	no	L0
hpv	Thrombotic disease	0-28	35	0.26	0.18–0.36	no	L0
hpv	SFN-1 symptom phenotype	0-28	2373	0.71	0.68–0.73	no	L0
hpv	SFN-2 peripheral-neuropathy phenotype	0-28	20	0.47	0.30–0.74	no	L0
hpv	SFN-3 autonomic phenotype	0-28	976	1.29	1.21–1.37	no	L0
hpv	POTS	0-28	43	5.30	3.84–7.31	yes	L1
hpv	Guillain-Barré syndrome	1-42	56	0.98	0.75–1.28	no	L0
hpv	Transverse myelitis	0-28	14	1.26	0.74–2.15	no	L0
hpv	Encephalitis	0-28	23	1.50	0.99–2.28	yes	L1
hpv	Optic neuritis	0-28	22	4.33	2.78–6.74	yes	L1
hpv	Bell's palsy	0-28	58	0.50	0.38–0.64	no	L0
hpv	Seizure	0-7	342	2.09	1.87–2.32	yes	L1
hpv	Thrombocytopenia	0-28	44	0.82	0.61–1.11	no	L0
hpv	TTS / thrombosis with thrombocytopenia	4-30	0	0.00	—–—	no	L0
hpv	Anaphylaxis	0-1	51	0.70	0.53–0.92	no	L0
hpv	Death (as reported)	0-28	44	0.27	0.20–0.36	no	L0
hpv	Appendicitis (negative control)	0-28	14	0.96	0.57–1.64	no	L0
hpv	Distal radius fracture (negative control)	0-28	2	1.79	0.43–7.42	no	L0
influenza	Myocarditis	0-7	21	0.16	0.10–0.24	no	L0
influenza	Pericarditis	0-7	57	0.51	0.39–0.66	no	L0
influenza	Arrhythmia	0-28	627	0.58	0.53–0.63	no	L0
influenza	Thrombotic disease	0-28	80	0.15	0.12–0.19	no	L0
influenza	SFN-1 symptom phenotype	0-28	15627	1.38	1.36–1.40	no	L0
influenza	SFN-2 peripheral-neuropathy phenotype	0-28	172	1.20	1.02–1.40	no	L0
influenza	SFN-3 autonomic phenotype	0-28	2365	0.87	0.83–0.90	no	L0
influenza	POTS	0-28	18	0.53	0.33–0.86	no	L0
influenza	Guillain-Barré syndrome	1-42	911	7.45	6.83–8.14	yes	L1
influenza	Transverse myelitis	0-28	127	4.30	3.48–5.31	yes	L1
influenza	Encephalitis	0-28	98	1.97	1.58–2.45	yes	L1
influenza	Optic neuritis	0-28	47	2.84	2.04–3.94	yes	L1
influenza	Bell's palsy	0-28	285	0.68	0.60–0.77	no	L0
influenza	Seizure	0-7	571	0.95	0.88–1.04	no	L0
influenza	Thrombocytopenia	0-28	188	1.00	0.86–1.16	no	L0
influenza	TTS / thrombosis with thrombocytopenia	4-30	0	0.00	—–—	no	L0
influenza	Anaphylaxis	0-1	332	1.34	1.20–1.51	no	L0
influenza	Death (as reported)	0-28	356	0.60	0.54–0.66	no	L0
influenza	Appendicitis (negative control)	0-28	5	0.09	0.04–0.21	no	L0
influenza	Distal radius fracture (negative control)	0-28	2	0.47	0.11–1.95	no	L0
meningococcal	Myocarditis	0-7	14	0.43	0.26–0.73	no	L0
meningococcal	Pericarditis	0-7	9	0.32	0.17–0.62	no	L0
meningococcal	Arrhythmia	0-28	154	0.57	0.48–0.67	no	L0
meningococcal	Thrombotic disease	0-28	6	0.05	0.02–0.11	no	L0
meningococcal	SFN-1 symptom phenotype	0-28	2597	0.85	0.82–0.89	no	L0
meningococcal	SFN-2 peripheral-neuropathy phenotype	0-28	13	0.34	0.20–0.58	no	L0
meningococcal	SFN-3 autonomic phenotype	0-28	864	1.25	1.17–1.34	no	L0
meningococcal	POTS	0-28	11	1.34	0.73–2.44	no	L0
meningococcal	Guillain-Barré syndrome	1-42	108	2.14	1.76–2.59	yes	L1
meningococcal	Transverse myelitis	0-28	18	1.81	1.13–2.90	yes	L1
meningococcal	Encephalitis	0-28	25	1.81	1.21–2.70	yes	L1
meningococcal	Optic neuritis	0-28	16	3.35	2.01–5.59	yes	L1
meningococcal	Bell's palsy	0-28	61	0.58	0.45–0.74	no	L0
meningococcal	Seizure	0-7	332	2.23	2.00–2.49	yes	L1
meningococcal	Thrombocytopenia	0-28	43	0.88	0.65–1.20	no	L0
meningococcal	TTS / thrombosis with thrombocytopenia	4-30	0	0.00	—–—	no	L0
meningococcal	Anaphylaxis	0-1	54	0.81	0.62–1.06	no	L0
meningococcal	Death (as reported)	0-28	22	0.15	0.10–0.22	no	L0
meningococcal	Appendicitis (negative control)	0-28	4	0.30	0.11–0.79	no	L0
meningococcal	Distal radius fracture (negative control)	0-28	1	0.96	0.13–7.00	no	L0
mmr	Myocarditis	0-7	4	0.07	0.03–0.20	no	L0
mmr	Pericarditis	0-7	3	0.06	0.02–0.20	no	L0
mmr	Arrhythmia	0-28	96	0.21	0.18–0.26	no	L0
mmr	Thrombotic disease	0-28	2	0.01	0.00–0.04	no	L0
mmr	SFN-1 symptom phenotype	0-28	962	0.19	0.18–0.20	no	L0
mmr	SFN-2 peripheral-neuropathy phenotype	0-28	9	0.14	0.07–0.27	no	L0
mmr	SFN-3 autonomic phenotype	0-28	293	0.25	0.23–0.28	no	L0
mmr	POTS	0-28	0	0.00	—–—	no	L0
mmr	Guillain-Barré syndrome	1-42	38	0.44	0.32–0.61	no	L0
mmr	Transverse myelitis	0-28	4	0.24	0.09–0.63	no	L0
mmr	Encephalitis	0-28	63	3.00	2.31–3.90	yes	L1
mmr	Optic neuritis	0-28	3	0.36	0.11–1.12	no	L0
mmr	Bell's palsy	0-28	39	0.22	0.16–0.31	no	L0
mmr	Seizure	0-7	256	1.03	0.91–1.17	no	L0
mmr	Thrombocytopenia	0-28	204	2.81	2.43–3.24	yes	L1
mmr	TTS / thrombosis with thrombocytopenia	4-30	0	0.00	—–—	no	L0
mmr	Anaphylaxis	0-1	137	1.30	1.10–1.55	no	L0
mmr	Death (as reported)	0-28	60	0.24	0.19–0.31	no	L0
mmr	Appendicitis (negative control)	0-28	1	0.04	0.01–0.32	no	L0
mmr	Distal radius fracture (negative control)	0-28	0	0.00	—–—	no	L0
other	Myocarditis	0-7	32	0.55	0.39–0.78	no	L0
other	Pericarditis	0-7	44	0.88	0.65–1.19	no	L0
other	Arrhythmia	0-28	385	0.79	0.72–0.88	no	L0
other	Thrombotic disease	0-28	59	0.26	0.20–0.34	no	L0
other	SFN-1 symptom phenotype	0-28	5650	1.04	1.02–1.07	no	L0
other	SFN-2 peripheral-neuropathy phenotype	0-28	79	1.18	0.94–1.48	no	L0
other	SFN-3 autonomic phenotype	0-28	1223	0.98	0.93–1.04	no	L0
other	POTS	0-28	7	0.46	0.22–0.97	no	L0
other	Guillain-Barré syndrome	1-42	259	3.04	2.67–3.46	yes	L1
other	Transverse myelitis	0-28	31	1.76	1.22–2.55	yes	L1
other	Encephalitis	0-28	54	2.26	1.71–3.00	yes	L1
other	Optic neuritis	0-28	14	1.58	0.92–2.73	yes	L1
other	Bell's palsy	0-28	120	0.63	0.53–0.76	no	L0
other	Seizure	0-7	234	0.84	0.74–0.96	no	L0
other	Thrombocytopenia	0-28	116	1.36	1.13–1.64	no	L0
other	TTS / thrombosis with thrombocytopenia	4-30	1	0.24	0.03–1.75	no	L0
other	Anaphylaxis	0-1	140	1.19	1.01–1.41	no	L0
other	Death (as reported)	0-28	172	0.64	0.55–0.74	no	L0
other	Appendicitis (negative control)	0-28	7	0.29	0.14–0.60	no	L0
other	Distal radius fracture (negative control)	0-28	2	1.08	0.26–4.47	no	L0
pcv	Myocarditis	0-7	5	0.06	0.02–0.14	no	L0
pcv	Pericarditis	0-7	9	0.12	0.06–0.23	no	L0
pcv	Arrhythmia	0-28	352	0.50	0.45–0.56	no	L0
pcv	Thrombotic disease	0-28	35	0.11	0.08–0.15	no	L0
pcv	SFN-1 symptom phenotype	0-28	8236	1.08	1.06–1.10	no	L0
pcv	SFN-2 peripheral-neuropathy phenotype	0-28	22	0.22	0.14–0.33	no	L0
pcv	SFN-3 autonomic phenotype	0-28	742	0.41	0.38–0.44	no	L0
pcv	POTS	0-28	2	0.09	0.02–0.36	no	L0
pcv	Guillain-Barré syndrome	1-42	124	0.94	0.78–1.13	no	L0
pcv	Transverse myelitis	0-28	20	0.77	0.49–1.20	no	L0
pcv	Encephalitis	0-28	71	2.14	1.67–2.75	yes	L1
pcv	Optic neuritis	0-28	1	0.07	0.01–0.52	no	L0
pcv	Bell's palsy	0-28	57	0.20	0.16–0.27	no	L0
pcv	Seizure	0-7	440	1.14	1.04–1.26	no	L0
pcv	Thrombocytopenia	0-28	139	1.15	0.96–1.36	no	L0
pcv	TTS / thrombosis with thrombocytopenia	4-30	0	0.00	—–—	no	L0
pcv	Anaphylaxis	0-1	89	0.52	0.42–0.64	no	L0
pcv	Death (as reported)	0-28	519	1.43	1.31–1.57	no	L0
pcv	Appendicitis (negative control)	0-28	2	0.06	0.01–0.23	no	L0
pcv	Distal radius fracture (negative control)	0-28	2	0.75	0.18–3.10	no	L0
polio	Myocarditis	0-7	2	0.12	0.03–0.50	no	L0
polio	Pericarditis	0-7	0	0.00	—–—	no	L0
polio	Arrhythmia	0-28	35	0.26	0.19–0.36	no	L0
polio	Thrombotic disease	0-28	3	0.05	0.02–0.15	no	L0
polio	SFN-1 symptom phenotype	0-28	339	0.22	0.20–0.25	no	L0
polio	SFN-2 peripheral-neuropathy phenotype	0-28	3	0.16	0.05–0.49	no	L0
polio	SFN-3 autonomic phenotype	0-28	137	0.39	0.33–0.47	no	L0
polio	POTS	0-28	0	0.00	—–—	no	L0
polio	Guillain-Barré syndrome	1-42	21	0.81	0.53–1.24	no	L0
polio	Transverse myelitis	0-28	1	0.20	0.03–1.39	no	L0
polio	Encephalitis	0-28	19	2.77	1.75–4.38	yes	L1
polio	Optic neuritis	0-28	0	0.00	—–—	no	L0
polio	Bell's palsy	0-28	13	0.25	0.14–0.43	no	L0
polio	Seizure	0-7	50	0.65	0.49–0.86	no	L0
polio	Thrombocytopenia	0-28	27	1.12	0.77–1.64	no	L0
polio	TTS / thrombosis with thrombocytopenia	4-30	0	0.00	—–—	no	L0
polio	Anaphylaxis	0-1	52	1.59	1.21–2.10	yes	L1
polio	Death (as reported)	0-28	37	0.50	0.36–0.69	no	L0
polio	Appendicitis (negative control)	0-28	0	0.00	—–—	no	L0
polio	Distal radius fracture (negative control)	0-28	0	0.00	—–—	no	L0
rotavirus	Myocarditis	0-7	2	0.11	0.03–0.43	no	L0
rotavirus	Pericarditis	0-7	2	0.12	0.03–0.49	no	L0
rotavirus	Arrhythmia	0-28	83	0.53	0.43–0.66	no	L0
rotavirus	Thrombotic disease	0-28	7	0.10	0.05–0.20	no	L0
rotavirus	SFN-1 symptom phenotype	0-28	22	0.01	0.01–0.02	no	L0
rotavirus	SFN-2 peripheral-neuropathy phenotype	0-28	0	0.00	—–—	no	L0
rotavirus	SFN-3 autonomic phenotype	0-28	32	0.08	0.06–0.11	no	L0
rotavirus	POTS	0-28	0	0.00	—–—	no	L0
rotavirus	Guillain-Barré syndrome	1-42	4	0.13	0.05–0.35	no	L0
rotavirus	Transverse myelitis	0-28	5	0.85	0.35–2.05	no	L0
rotavirus	Encephalitis	0-28	22	2.77	1.81–4.24	yes	L1
rotavirus	Optic neuritis	0-28	0	0.00	—–—	no	L0
rotavirus	Bell's palsy	0-28	8	0.13	0.07–0.26	no	L0
rotavirus	Seizure	0-7	176	2.01	1.73–2.33	yes	L1
rotavirus	Thrombocytopenia	0-28	24	0.85	0.57–1.28	no	L0
rotavirus	TTS / thrombosis with thrombocytopenia	4-30	0	0.00	—–—	no	L0
rotavirus	Anaphylaxis	0-1	10	0.26	0.14–0.48	no	L0
rotavirus	Death (as reported)	0-28	332	4.07	3.64–4.54	yes	L1
rotavirus	Appendicitis (negative control)	0-28	1	0.13	0.02–0.92	no	L0
rotavirus	Distal radius fracture (negative control)	0-28	0	0.00	—–—	no	L0
varicella	Myocarditis	0-7	11	0.10	0.06–0.18	no	L0
varicella	Pericarditis	0-7	12	0.13	0.07–0.22	no	L0
varicella	Arrhythmia	0-28	226	0.25	0.22–0.28	no	L0
varicella	Thrombotic disease	0-28	31	0.07	0.05–0.10	no	L0
varicella	SFN-1 symptom phenotype	0-28	7560	0.77	0.75–0.79	no	L0
varicella	SFN-2 peripheral-neuropathy phenotype	0-28	66	0.53	0.41–0.67	no	L0
varicella	SFN-3 autonomic phenotype	0-28	1093	0.47	0.45–0.50	no	L0
varicella	POTS	0-28	3	0.11	0.03–0.33	no	L0
varicella	Guillain-Barré syndrome	1-42	119	0.70	0.58–0.84	no	L0
varicella	Transverse myelitis	0-28	24	0.72	0.48–1.10	no	L0
varicella	Encephalitis	0-28	63	1.46	1.12–1.89	no	L0
varicella	Optic neuritis	0-28	11	0.66	0.36–1.22	no	L0
varicella	Bell's palsy	0-28	166	0.48	0.41–0.56	no	L0
varicella	Seizure	0-7	262	0.51	0.45–0.58	no	L0
varicella	Thrombocytopenia	0-28	157	1.02	0.87–1.20	no	L0
varicella	TTS / thrombosis with thrombocytopenia	4-30	0	0.00	—–—	no	L0
varicella	Anaphylaxis	0-1	153	0.71	0.60–0.84	no	L0
varicella	Death (as reported)	0-28	122	0.24	0.20–0.29	no	L0
varicella	Appendicitis (negative control)	0-28	2	0.04	0.01–0.18	no	L0
varicella	Distal radius fracture (negative control)	0-28	2	0.58	0.14–2.42	no	L0

Reproduce: python -m vaccine_safety run-phase1. SCCS/cohort: python -c "from vaccine_safety.analyses.sccs import run; run()" raises by design. Protocol: vaccine_safety/config/analyses/phase1_protocol.json. Evidence against any association is in the evidence_item table (reporting bias, infection confounding, SFN-not-confirmed).